News Column

2013 Pharmaceutical Compliance Congress Co-chairs Announced

Oct. 4, 2012

CBI is pleased to announce the Congress Co-Chairs for PCC 2013 - CBI's 10(th) Annual Pharmaceutical Compliance Congress, taking place January 29-30, 2013 at the Ritz-Carlton in Washington, DC. The Congress is the premier compliance meeting for life sciences executives. PCC unites Chief Compliance Officers and their industry compliance, legal and regulatory peers to benchmark and share best practices and innovative approaches for successful corporate compliance programs (see also Pharmaceutical Companies).

This year's Congress Co-Chairs are Kris Curry, Vice President, Health Care Compliance, Pharmaceuticals Group, Johnson & Johnson and Cynthia "Cindy" Cetani, Vice President, Ethics & Compliance and Chief Compliance Officer, Novartis Pharmaceuticals Corporation. Curry and Cetani take the reins in 2013 from past Congress Chairs, including Doug Lankler, Executive Vice President and Chief Compliance and Risk Officer, Pfizer, and Michael Shaw, Vice President and Chief Compliance Officer, North America Pharmaceuticals, GlaxoSmithKline.

Curry is the global leader of Johnson & Johnson Pharmaceuticals' Health Care Compliance Program. She is recognized by her colleagues and peers as a results-oriented leader with demonstrated ability to implement large-scale project improvements that drive efficiencies and reduce overall costs. She has a reputation for building and developing high-performing teams with versatile and diverse experiences.

Cetani is Vice President and Chief Compliance Officer at Novartis Pharmaceuticals. In this role, she oversees the company's Corporate Compliance Program and, coordinating with the legal department, is responsible for establishing standards and policies pertaining to regulatory requirements to help ensure legal, ethical and proper conduct.

PCC boasts an executive-level industry speaking faculty, including representation from Auxilium, Biogen Idec, Boehringer Ingelheim, Celgene, Dendreon, Incyte, Ipsen, Meda, Medicis, Par, Pfizer, Purdue, Sunovion, Takeda, Teva, UCB and Vertex, as well as government perspectives from the DOJ, CMS and FDA.



Source: Copyright 2012, NewsRx LLC


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters